ADiTx Therapeutics Inc. (ADTX) News
Filter ADTX News Items
ADTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ADTX News From Around the Web
Below are the latest news stories about ADITXT INC that investors may wish to consider to help them evaluate ADTX as an investment opportunity.
Why Is Aditxt (ADTX) Stock Up 70% Today?Aditxt stock is rising higher on Thursday as investors react to heavy trading of ADTX shares despite a lack of news today. |
Why Is Connexa Sports Technologies (CNXA) Stock Up 31% Today?Connexa Sports Technologies stock is rising on a new 5.9% CNXA shareholder and a secondary offering from one of its investors. |
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?Redhill Biopharma stock is falling on Thursday as shares of RDHL give up some of the gains they made throughout the week. |
Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?Vivos Therapeutics stock is falling on Thursday but that's only after VVOS shares experienced a massive rally on Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Aditxt, Inc. to Present at 8th Annual Dawson James ConferenceChief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023Richmond, VA, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt” or the "Company"), an innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system will present at the 8th Annual Dawson James Conference on Thursday, October 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, |
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me PlatformMOUNTAIN VIEW, Calif., October 05, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. T |
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceJUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu |
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023RICHMOND, Va. & MOUNTAIN VIEW, Calif., September 08, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel |
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq RulesRICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) an |